Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical Dorzolamide–Brimonidine Plus Intravitreal Bevacizumab in Diabetic Macular Edema
IRCT20260315068989N1Phase 3Recruiting
- Sponsor
- Ahvaz Jundishapur University of Medical Sciences
- Start
- Mar 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of dorzolamide, brimonidine and bevacizumab in diabetic macular edema (DME), sponsored by Ahvaz Jundishapur University of Medical Sciences. Started Mar 2026; status: recruiting.
02
Drugs
dorzolamidebrimonidinebevacizumab
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on IRCT20260315068989N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20260315068989N1.